Expert opinion on pharmacotherapy · 2026
Pharmacotherapeutic interventions for pediatric ulcerative colitis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Romano Alessia, Vazzana Giovanna Fernanda, Romano Claudio
Аннотация
INTRODUCTION: Pediatric ulcerative colitis (UC) is a chronic, immune-mediated inflammatory disease of the colon, characterized by dysregulated immune response. This condition significantly impacts growth, development, and quality of life, highlighting the need for effective therapeutic strategies.
AREAS COVERED: This report reviews current pharmacologic treatments for pediatric UC, including conventional (aminosalicylates, corticosteroids, immunomodulators) and advanced therapies (biologics, small molecules). It discusses their mechanisms, efficacy, and safety, highlights challenges such as inadequate response and the need for precision medicine, and summarizes emerging therapies, ongoing pediatric trials, and novel agents under development. A comprehensive literature search of PubMed, Embase, and Cochrane Library databases (1987-2026) identified 100 studies: 67 pediatric-specific and 33 adult studies. The review included randomized controlled trials, observational studies, systematic reviews, and clinical practice guidelines (ECCO-ESPGHAN, NASPGHAN).
EXPERT OPINION: Optimal management of pediatric UC requires a personalized approach that balances efficacy and safety while anticipating long-term outcomes. Integration of novel biologics, targeted therapies, and precision medicine strategies holds promise for improving disease control, minimizing adverse effects, and enhancing quality of life in affected children.
AREAS COVERED: This report reviews current pharmacologic treatments for pediatric UC, including conventional (aminosalicylates, corticosteroids, immunomodulators) and advanced therapies (biologics, small molecules). It discusses their mechanisms, efficacy, and safety, highlights challenges such as inadequate response and the need for precision medicine, and summarizes emerging therapies, ongoing pediatric trials, and novel agents under development. A comprehensive literature search of PubMed, Embase, and Cochrane Library databases (1987-2026) identified 100 studies: 67 pediatric-specific and 33 adult studies. The review included randomized controlled trials, observational studies, systematic reviews, and clinical practice guidelines (ECCO-ESPGHAN, NASPGHAN).
EXPERT OPINION: Optimal management of pediatric UC requires a personalized approach that balances efficacy and safety while anticipating long-term outcomes. Integration of novel biologics, targeted therapies, and precision medicine strategies holds promise for improving disease control, minimizing adverse effects, and enhancing quality of life in affected children.